Asian stocks rise on hopes for drug to treat coronavirus
DECCAN CHRONICLE | DC Correspondent
HONG KONG: Asian markets rallied again and oil prices built on the previous day's surge as investors began to see a glimmer of light at the end of the tunnel in the fight against coronavirus, following news of a possible breakthrough in the search for a treatment.
Top US epidemiologist Anthony Fauci's comments that Gilead Science's remdesivir "has a clear-cut, significant, positive effect in diminishing the time to recovery" fanned hopes that lockdowns already being loosened in some nations could be lifted more quickly, allowing people back to work to kickstart the battered economy.
The announcement allowed investors to look past data showing the US economy had contracted 4.8 percent in the first quarter, its worst performance in a decade, and the Federal Reserve's warning that it would likely tank even further in April-June.
The central bank did provide some support, though, by pledging to keep interest rates at zero until the economy has weathered the crisis and is ready to resume growth. On Thursday France said its economy had fared even worse and contracted 5.8 percent.
"While a treatment is not a vaccine, a successful treatment would be a game-changer for the virus and would help facilitate a greater rollback of containment measures," said National Australia Bank's Tapas Strickland.
"It could also give consumers greater confidence to resume pre-pandemic activity."
Wall Street and Europe's main indexes all rose at least two percent, and Asian equities already enjoying a bright week on signs of an easing in the virus took up the baton Thursday.
Tokyo returned from a one-day holiday to end 2.1 percent higher, while Sydney, Singapore, Taipei and Jakarta also piled on more than two percent.
Mumbai jumped three percent, with Shanghai, Manila and Bangkok breaking the one percent mark, though Wellington dropped more than one percent.
Hong Kong and Seoul were closed for public holidays.
"One of the main reasons for the strong recovery in risk sentiment... is the homogeneity of the recession's driver," said AxiCorp's Stephen Innes.
"Compared to previous downturns that were more multifaceted and professedly more difficult to unwind, the eradication of the single recessionary input -- the virus -- via a vaccine can cobblestone the way for an expeditious recovery in global economic output."